These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25023406)

  • 1. ERCC polymorphisms and prognosis of patients with osteosarcoma.
    Li J; Liu S; Wang W; Zhang K; Liu Z; Zhang C; Chen S; Wu S
    Tumour Biol; 2014 Oct; 35(10):10129-36. PubMed ID: 25023406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letter regarding Li JS et al. entitled "ERCC polymorphisms and prognosis of patients with osteosarcoma".
    Jian Y; Tian X; Li B; Zhou Z; Wu X
    Tumour Biol; 2015 May; 36(5):3195-6. PubMed ID: 25824708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients.
    Hao T; Feng W; Zhang J; Sun YJ; Wang G
    Asian Pac J Cancer Prev; 2012; 13(8):3821-4. PubMed ID: 23098477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between common polymorphisms in ERCC gene and glioma risk: A meta-analysis of 15 studies.
    Qian T; Zhang B; Qian C; He Y; Li Y
    Medicine (Baltimore); 2017 May; 96(20):e6832. PubMed ID: 28514298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
    Zhang H; Ge J; Hong H; Bi L; Sun Z
    World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of ERCC gene polymorphism with osteosarcoma risk.
    Wang G; Li J; Xu X; Gupta RK; Gao X
    Afr Health Sci; 2020 Dec; 20(4):1840-1848. PubMed ID: 34394247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC polymorphisms and risk of osteosarcoma: a meta-analysis.
    Chen XJ; Tong ZC; Kang X; Wang ZC; Huang GL; Yang TM; Dong L
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6658-6666. PubMed ID: 30402838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy: A meta-analysis in Chinese population.
    Liu D; Liu X
    Medicine (Baltimore); 2018 Dec; 97(49):e13358. PubMed ID: 30544402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors.
    Yang LM; Li XH; Bao CF
    Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
    Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
    Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
    Ji WP; He NB
    Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of ERCC1 C8092A and ERCC2 Lys751Gln polymorphisms with the risk of glioma: a meta-analysis.
    Xin Y; Hao S; Lu J; Wang Q; Zhang L
    PLoS One; 2014; 9(4):e95966. PubMed ID: 24763305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Analysis of Influence ERCC Polymorphisms Confer on the Development of Brain Tumors.
    Geng P; Ou J; Li J; Liao Y; Wang N; Xie G; Sa R; Liu C; Xiang L; Liang H
    Mol Neurobiol; 2016 May; 53(4):2705-14. PubMed ID: 26264164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
    Sun Y; Wu Y; Li W; Kong Z; Zou X
    Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
    Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
    BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma.
    Schrama D; Scherer D; Schneider M; Zapatka M; Bröcker EB; Schadendorf D; Ugurel S; Kumar R; Becker JC
    J Invest Dermatol; 2011 Jun; 131(6):1280-90. PubMed ID: 21390047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.
    Varma A; Mathaiyan J; Shewade D; Dubashi B; Sunitha K
    J Clin Pharm Ther; 2020 Aug; 45(4):617-627. PubMed ID: 32399998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
    Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
    Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
    Lu X; Xiao S; Jin C; van der Straaten T; Li X
    J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.